INNT vs. ONCSQ, NOVNQ, UTRS, GNCA, HTGMQ, KLDO, VIVE, AHPI, HGEN, and CNTX
Should you be buying Innovate Biopharmaceuticals stock or one of its competitors? The main competitors of Innovate Biopharmaceuticals include OncoSec Medical (ONCSQ), NVN Liquidation (NOVNQ), Minerva Surgical (UTRS), Genocea Biosciences (GNCA), HTG Molecular Diagnostics (HTGMQ), Kaleido Biosciences (KLDO), Viveve Medical (VIVE), Allied Healthcare Products (AHPI), Humanigen (HGEN), and Context Therapeutics (CNTX). These companies are all part of the "medical" sector.
Innovate Biopharmaceuticals (NASDAQ:INNT) and OncoSec Medical (NASDAQ:ONCSQ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings, profitability and community ranking.
Innovate Biopharmaceuticals received 203 more outperform votes than OncoSec Medical when rated by MarketBeat users.
In the previous week, Innovate Biopharmaceuticals had 4 more articles in the media than OncoSec Medical. MarketBeat recorded 4 mentions for Innovate Biopharmaceuticals and 0 mentions for OncoSec Medical. Innovate Biopharmaceuticals' average media sentiment score of 0.00 equaled OncoSec Medical'saverage media sentiment score.
Innovate Biopharmaceuticals has a beta of -0.39, meaning that its stock price is 139% less volatile than the S&P 500. Comparatively, OncoSec Medical has a beta of -18.22, meaning that its stock price is 1,922% less volatile than the S&P 500.
5.9% of Innovate Biopharmaceuticals shares are owned by institutional investors. 7.9% of Innovate Biopharmaceuticals shares are owned by company insiders. Comparatively, 1.3% of OncoSec Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Innovate Biopharmaceuticals beats OncoSec Medical on 6 of the 7 factors compared between the two stocks.
Get Innovate Biopharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for INNT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Innovate Biopharmaceuticals Competitors List
Related Companies and Tools
